- Home
- RYDE vs SILO Comparison
RYDE vs SILO Comparison
Compare RYDE & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- SILO
- Stock Information
- Founded
- RYDE 2014
- SILO 2010
- Country
- RYDE Singapore
- SILO United States
- Employees
- RYDE N/A
- SILO N/A
- Industry
- RYDE
- SILO Apparel
- Sector
- RYDE
- SILO Consumer Discretionary
- Exchange
- RYDE NYSE
- SILO Nasdaq
- Market Cap
- RYDE 5.2M
- SILO 4.5M
- IPO Year
- RYDE 2024
- SILO N/A
- Fundamental
- Price
- RYDE $0.36
- SILO $0.61
- Analyst Decision
- RYDE
- SILO
- Analyst Count
- RYDE 0
- SILO 0
- Target Price
- RYDE N/A
- SILO N/A
- AVG Volume (30 Days)
- RYDE 29.7M
- SILO 316.2K
- Earning Date
- RYDE 05-02-2025
- SILO 08-12-2025
- Dividend Yield
- RYDE N/A
- SILO N/A
- EPS Growth
- RYDE N/A
- SILO N/A
- EPS
- RYDE N/A
- SILO N/A
- Revenue
- RYDE $6,557,978.00
- SILO $72,102.00
- Revenue This Year
- RYDE $21.13
- SILO $1.86
- Revenue Next Year
- RYDE $13.43
- SILO N/A
- P/E Ratio
- RYDE N/A
- SILO N/A
- Revenue Growth
- RYDE 3.27
- SILO N/A
- 52 Week Low
- RYDE $0.16
- SILO $0.41
- 52 Week High
- RYDE $22.49
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- SILO 48.15
- Support Level
- RYDE N/A
- SILO $0.60
- Resistance Level
- RYDE N/A
- SILO $0.64
- Average True Range (ATR)
- RYDE 0.00
- SILO 0.04
- MACD
- RYDE 0.00
- SILO 0.01
- Stochastic Oscillator
- RYDE 0.00
- SILO 48.98
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.